RYTM - Rhythm Pharma announces positive data from phase 3 trial of obesity treatment

• Rhythm Pharma ( NASDAQ: RYTM ) said on Monday that patients with a rare genetic disease called Bardet-Biedl syndrome and obesity showed clinically meaningful improvements across multiple health-related quality of life when tested with its therapy, setmelanotide, in a phase 3 trial.
• The company said about 20 patients with Bardet-Biedl syndrome and obesity reported clinically meaningful improvements across multiple health-related quality-of-life measures following 52 weeks of treatment with setmelanotide.
• Bardet-Biedl syndrome is a rare genetic syndromic disease with various symptoms that evolve over time including visual impairments, renal disease, polydactyly, genital abnormalities, cognitive impairment, hyperphagia, and early-onset, severe obesity arising from impairment of the hypothalamic of rare melanocortin-4 receptor pathway.

For further details see: